Form 4: Terns Pharmaceuticals Acquired by Merck

Director Robert Azelby reports the cancellation of stock options following the completion of the merger between Terns Pharmaceuticals and Merck.

Summary

• Terns Pharmaceuticals, Inc. has been acquired by Merck Sharp & Dohme LLC.
• The acquisition was executed via a tender offer at a price of $53.00 per share.
• Reporting person Robert Azelby had outstanding stock options cancelled and converted into the right to receive the cash difference between the merger consideration and the exercise price.
• The transaction was finalized on May 5, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a liquidity event at a defined cash price.

Positives

• Shareholders received a cash consideration of $53.00 per share.
• The merger successfully reached completion following the tender offer process.

Negatives

• The company will no longer trade as an independent public entity.

Risks

• None, as the company has been acquired and the transaction is complete.

Future Outlook

The company has been acquired by Merck; therefore, no further independent forward-looking guidance is provided.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the pharmaceutical sector, with Merck continuing its strategy of acquiring specialized biotech firms to bolster its pipeline.

Comparison to Industry Standards

• The $53.00 per share cash offer is consistent with typical premium-based acquisitions in the mid-cap biotechnology sector.
• The use of a tender offer is a standard mechanism for rapid acquisition completion in the pharmaceutical industry.

Stakeholder Impact

• Shareholders receive cash for their holdings.
• Employees and management transition to the acquiring entity, Merck.

Next Steps

• Delisting of Terns Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

Merger, Acquisition, Terns Pharmaceuticals, Merck, Tender Offer, Form 4